SLC5A2 and type 2 diabetes mellitus: The Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients-Removing Excess Glucose (EMPA-REG OUTCOME) study was the first to demonstrate a reduced risk of incident or worsening nephropathy with sodium-glucose cotransporter-2 inhibitor (SGLT2-i) inhibition.